Haussier
Pfizer's stock rises 2.15% to $28.57 amid Q2 earnings beat and raised revenue guidance.
Ce briefing n’est pas encore disponible dans cette langue — version anglaise affichée.
Pfizer's stock price increased by 2.15% to $28.57 following a strong Q2 earnings report and an upward revision of its 2026 revenue guidance. The company reported Q2 revenue of $15.03 billion, surpassing expectations, and raised its full-year revenue guidance midpoint by $500 million.
Points clés
- Pfizer's Q2 2026 earnings exceeded expectations, with revenue of $15.03 billion and adjusted EPS of $0.77.
- The company raised its full-year 2026 revenue guidance midpoint by $500 million, indicating confidence in its financial performance.
- Analysts have set an average price target of $28.28 for Pfizer, suggesting limited upside from the current price.
- Institutional investors have shown mixed reactions, with some increasing their holdings and others reducing them, reflecting a cautious outlook.
Sources
- Pfizer Reports Second-Quarter Results And Raises Midpoint of 2026 Revenue GuidanceBusiness Wire · August 4, 2026
- Pfizer stock trades just below analyst targets as Q2 earnings and guidance shape 2026 outlookAD HOC NEWS · August 25, 2026
- Pfizer Inc. $PFE Stock Position Lowered by Cibc World Market Inc.MarketBeat · August 25, 2026
- Pfizer Inc. $PFE Shares Sold by Bank of Nova ScotiaMarketBeat · August 25, 2026
Généré par IA à partir de sources d'actualités publiques. Ceci n'est pas un conseil financier.
